Dr. Kyle W. Rickner, M.D
Family Medicine (Family Medicine Physician)
At a glance
- In the NPI registry since
- 2006
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Family Medicine Physician primary
OK license 21266
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Jardiance (empagliflozin) Other prescribers in Edmond, OK | 57 |
| Levothyroxine Sodium Other prescribers in Edmond, OK | 42 |
| Abrysvo (rsv vacc, pref a and pref b/pf) Other prescribers in Edmond, OK | 39 |
| Quetiapine Fumarate Other prescribers in Edmond, OK | 31 |
| Pantoprazole Sodium Other prescribers in Edmond, OK | 26 |
| Shingrix (varicella-zoster ge/as01b/pf) Other prescribers in Edmond, OK | 23 |
| Citalopram Hbr (citalopram hydrobromide) Other prescribers in Edmond, OK | 19 |
| Atorvastatin Calcium Other prescribers in Edmond, OK | 19 |
| Cyclobenzaprine Hcl Other prescribers in Edmond, OK | 17 |
| Hydrochlorothiazide Other prescribers in Edmond, OK | 16 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 8 payments worth $154 in total to this clinician.
| AbbVie Inc. | $45.36 |
|---|---|
| Sumitomo Pharma America, Inc. | $21.70 |
| Otsuka America Pharmaceutical, Inc. | $19.59 |
| Amgen Inc. | $18.70 |
| AstraZeneca Pharmaceuticals LP | $17.45 |
| Astellas Pharma US Inc | $16.51 |
| Ibsa Pharma Inc. | $15.01 |
| Food and Beverage | $154 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 19 industry-funded studies in 2025, from 9 companies. The companies reported $1,454,930 in research payments for these studies, mostly to the institutions running them.
- A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis
ModernaTX, Inc. · Active, not recruiting · NCT06592794 - A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age
ModernaTX, Inc. · Completed · NCT06602024 - A Phase I/II, Double-blinded, Randomized, Placebo-Controlled, Dose Selection Study in Adults to Assess the Safety and Immunogenicity of AZD4117 and AZD5315 Vaccines PANDA
AstraZeneca Pharmaceuticals LP - A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age
ModernaTX, Inc. · Completed · NCT05575492 - A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants
ModernaTX, Inc. · Completed · NCT05831111 - CT-388-104 OW/OB with T2D
Genentech, Inc. - A phase 3 study to evaluate the efficacy immunogenicity and safety of respiratory syncytial virus rsv prefusion f subunit vaccine in adults
Pfizer Inc. - A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with establish…
Boehringer Ingelheim Pharmaceuticals, Inc. - A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age
ModernaTX, Inc. · Completed · NCT05127434 - A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in p…
Boehringer Ingelheim Pharmaceuticals, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.